Myeloproliferative neoplasms (MPNs), including polycythemia vera, essential thrombocythemia, and primary myelofibrosis, may lead to gastroesophageal varices. The quality of life, morbidity, and mortality of MPN patients mainly depend on disease-related symptoms, thromboembolic and hemorrhagic complications. Previous studies have shown that JAK2 V617F has a prominent role in vascular risk and MPN-associated gastroesophageal varices. Portal vein thrombosis and portal cavernoma frequently occur in the MPN population and the management of gastroesophageal varices in these patients are sometimes technically difficult. The aim of this study is to investigate the the characteristics of patients with gastroesophageal varices and portal caver cavernoma with or without JAK2 mutation.
Name: JAK2 mutation test
Description: Have a history of the occurrence of gastroesophageal variceal bleedingMeasure: History of variceal bleeding Time: 1 day (the same time as diagnosis)
Description: 1-year death rateMeasure: 1-year death rate Time: 1 year
Description: The concurrence of complications of portal hypertension (ascites, infections, variceal bleeding, et al)Measure: Complications of portal hypertension Time: 1 year
There is one SNP
Previous studies have shown that JAK2 V617F has a prominent role in vascular risk and MPN-associated gastroesophageal varices. --- V617F ---